A detailed history of Goldman Sachs Group Inc transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 700,892 shares of CRBU stock, worth $1.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
700,892
Previous 1,188,764 41.04%
Holding current value
$1.26 Million
Previous $1.95 Million 29.91%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.56 - $2.73 $761,080 - $1.33 Million
-487,872 Reduced 41.04%
700,892 $1.37 Million
Q2 2024

Aug 13, 2024

BUY
$1.62 - $5.05 $949,096 - $2.96 Million
585,862 Added 97.17%
1,188,764 $1.95 Million
Q1 2024

May 15, 2024

SELL
$4.82 - $8.26 $275,405 - $471,959
-57,138 Reduced 8.66%
602,902 $3.1 Million
Q4 2023

Feb 13, 2024

BUY
$3.58 - $6.25 $946,662 - $1.65 Million
264,431 Added 66.84%
660,040 $3.78 Million
Q3 2023

May 14, 2024

SELL
$4.08 - $8.14 $1.08 Million - $2.15 Million
-264,431 Reduced 40.06%
395,609 $1.89 Million
Q3 2023

Nov 14, 2023

BUY
$4.08 - $8.14 $509,869 - $1.02 Million
124,968 Added 46.17%
395,609 $1.89 Million
Q2 2023

May 14, 2024

SELL
$4.04 - $5.47 $174,237 - $235,910
-43,128 Reduced 13.75%
270,641 $1.15 Million
Q2 2023

Aug 14, 2023

SELL
$4.04 - $5.47 $174,237 - $235,910
-43,128 Reduced 13.75%
270,641 $1.15 Million
Q1 2023

May 14, 2024

SELL
$4.3 - $7.78 $168,250 - $304,415
-39,128 Reduced 11.09%
313,769 $1.67 Million
Q1 2023

May 11, 2023

SELL
$4.3 - $7.78 $168,250 - $304,415
-39,128 Reduced 11.09%
313,769 $1.67 Million
Q4 2022

May 14, 2024

SELL
$5.57 - $11.01 $1.2 Million - $2.37 Million
-215,432 Reduced 37.91%
352,897 $2.22 Million
Q4 2022

Feb 13, 2023

SELL
$5.57 - $11.01 $1.2 Million - $2.37 Million
-215,432 Reduced 37.91%
352,897 $2.22 Million
Q3 2022

May 14, 2024

BUY
$5.34 - $12.79 $2.29 Million - $5.47 Million
428,011 Added 305.03%
568,329 $6 Million
Q3 2022

Nov 10, 2022

BUY
$5.34 - $12.79 $2.29 Million - $5.47 Million
428,011 Added 305.03%
568,329 $6 Million
Q2 2022

May 14, 2024

SELL
$5.1 - $9.74 $2.65 Million - $5.06 Million
-519,722 Reduced 78.74%
140,318 $761,000
Q2 2022

Aug 15, 2022

SELL
$5.1 - $9.74 $709,614 - $1.36 Million
-139,140 Reduced 49.79%
140,318 $761,000
Q1 2022

May 16, 2022

BUY
$8.42 - $15.32 $2.09 Million - $3.8 Million
247,735 Added 780.93%
279,458 $2.57 Million
Q4 2021

Feb 14, 2022

BUY
$14.59 - $23.26 $462,838 - $737,876
31,723 New
31,723 $478,000

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $110M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.